Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Corbus Pharmaceuticals ( (CRBP) ).
Corbus Pharmaceuticals reported its third quarter 2025 financial results, highlighting significant progress in its clinical programs. The company presented promising data for CRB-701 at ESMO 2025, with plans to start a registrational study in mid-2026. Additionally, Corbus completed a $75 million public offering, extending its cash runway into 2028, and is on track to advance its CRB-913 program for obesity treatment by the end of 2025. The financial results showed an increased net loss due to higher clinical development expenses, but the company’s strong cash position supports its operations and future plans.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on oncology and obesity, headquartered in Norwood, Massachusetts. The company’s pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody for solid tumors; and CRB-913, a CB1 receptor inverse agonist for obesity treatment.
Average Trading Volume: 311,634
Technical Sentiment Signal: Sell
Current Market Cap: $128.2M
For a thorough assessment of CRBP stock, go to TipRanks’ Stock Analysis page.